Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

AUSTIN, Texas & CAMBRIDGE, Mass.–Sept. 6, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, updates Proactive Investors on company operations in the last few months, notably raising $10 million to be used toward continuing the company’s clinical trial of Oncoprex. CEO, Rodney Varner, discusses resuming enrollment in Phase 1 and 2 studies for Oncoprex and recent agreements with the University of Texas MD Anderson Cancer Center.

Full interview can be viewed here.